The effect of concomitant use of proton pump inhibitors with CDK 4/6 inhibitors on survival in metastatic breast cancer

Basit Öğe Kaydı
dc.contributor.authorCaglayan, Dilek
dc.contributor.authorKocak, Mehmet Zahid
dc.contributor.authorGeredeli, Caglayan
dc.contributor.authorTatli, Ali Murat
dc.contributor.authorGoksu, Sema Sezgin
dc.contributor.authorEryilmaz, Melek Karakurt
dc.contributor.authorAraz, Murat
dc.date.accessioned2024-02-23T13:43:32Z
dc.date.available2024-02-23T13:43:32Z
dc.date.issued2023
dc.departmentNEÜen_US
dc.description.abstractAim To evaluate the difference of progression free survival between the patients using concomitant proton pump inhibitors and non-users in the patients using CDK 4/6 inhibitors with HR + and HER2 negative mBC. Methods We included 86 patients with HR + and HER 2 negative mBC treated with CDK 4/6 inhibitors in this study. Patients were divided into two categories according to their status of PPI use. The primary end points was progression free survival (PFS). We compared PPI users and non-users. Results Forty-five (52.3%) patients used a PPI concomitantly with a CDK 4/6 inhibitor, and 41 (47.7%) did not. The median duration of follow-up was 10.68 (1.94-27.56) months. Of the patients, 50 (58.1%) palbociclib and 36 (41.9%) received ribociclib. The median progression free survival (mPFS) was 10.9 months (95% CI: 7.5-14.27) in the group with concomitant PPI use with a CDK 4/6 inhibitor, whereas the median progression free survival could not be reached in the group without concomitant PPI use (p = 0.04). In addition, concomitant PPI use with palbociclib was associated with a shorter PFS; there was no significant difference between the concomitant PPI users and non-users in terms of PFS in the patients using ribociclib. Conclusion Palbociclib and ribociclib are weak base drugs so their bioavailability is pH-dependent. PPIs can affect their solubility and their concentration in the plasma. Therefore, we must avoid concomitant use of PPIs and CDK 4/6 inhibitors. If we need to use concomitant PPI and CDK 4/6 inhibitors, we should prefer ribociclib than palbociclib.en_US
dc.identifier.doi10.1007/s00228-022-03435-7
dc.identifier.endpage248en_US
dc.identifier.issn0031-6970
dc.identifier.issn1432-1041
dc.identifier.issue2en_US
dc.identifier.pmid36520173en_US
dc.identifier.scopus2-s2.0-85144138421en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage243en_US
dc.identifier.urihttps://doi.org/10.1007/s00228-022-03435-7
dc.identifier.urihttps://hdl.handle.net/20.500.12452/10850
dc.identifier.volume79en_US
dc.identifier.wosWOS:000899439100001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Heidelbergen_US
dc.relation.ispartofEuropean Journal Of Clinical Pharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCdk 4en_US
dc.subject6 Inhibitorsen_US
dc.subjectProton Pump Inhibitorsen_US
dc.subjectProgression Free Survivalen_US
dc.subjectPalbocicliben_US
dc.subjectRibocicliben_US
dc.titleThe effect of concomitant use of proton pump inhibitors with CDK 4/6 inhibitors on survival in metastatic breast canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu